University of California, Los Angeles Neuro-Oncology : Translational Research : Leia Nghiemphu M.D.

Contact Us \| Directions \| Referring a Patient
A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis, cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.

Home > Translational Research > Leia Nghiemphu M.D.

Leia Nghiemphu M.D.

The Ronald Reagan Hospital at
UCLA Medical Center
710 Westwood Plaza
Reed Bldg RM 1-230
Los Angeles CA 90095

• Assistant Clinical Professor

Attending:
Neurology, UCLA School of Medicine, 2003 - Present

Clinical Fellowship:
Neuro-Oncology Program, Department of Neurology
David Geffen School of Medicine at UCLA, 2003 - 2006

Translational Investigation Fellowship:
Track II of UCLA K30 Graduate Training Program in Translational Investigation
David Geffen School of Medicine at UCLA, 2004 - 2006

Research Fellowship:
Lab of Ingo Mellinghoff, M.D., Department of Molecular & Medical Pharmacology
David Geffen School of Medicine at UCLA, 2004 - 2006

Medical Board Certification:
Neurology, American Board of Psychiatry and Neurology, 2004 - Present

Residency:
Neurology, Stanford University Medical Center, 2000 - 2003

Internship:
Internal Medicine, Beth Israel Medical Center, 1999 - 2000

Medical Degree:
Albert Einstein College of Medicine, Bronx, NY, 1995 - 1999

Research Interests

Published Findings


Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell PMID: 19573811 ; 16(1):44-54.	Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252(1):182-9.PMID: 19561256	Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 7;72(14):1217-22.

Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol PMID: 18436627	Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol. PMID: 18389177	Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. Int J Radiat Oncol Biol Phys PMID: 18355978

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. PMID: 18215105	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma Proc Natl Acad Sci PMID: 18077431	Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 Clin Cancer Res PMID: 17473188 (9):2592-8.

Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Medicine PMID: 17177598 ; 3(12):e485	MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8):1258-60. PMID: 16636248

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, Provider^IQ) 1998-2010 SiliconMED North America

Provider^IQ is a registered trademark of SiliconMED North America and used by permission.

[Content Published:9/4/2010 10:15:14 AM PST]